Overview

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream when it is given at the same dose 7 days apart, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Glucagon-Like Peptide 1
rGLP-1 protein